RA
CGON icon

Rosalind Advisors’s CG Oncology CGON Stock Holding History

Rosalind Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.77M Sell
100,000
-200,000
-67% -$11.3M 2.72% 14
2025
Q4 		$12.5M Hold
300,000
– – 4.38% 12
2025
Q3 		$12.1M Buy
300,000
+107,026
+55% +$3.11M 4.13% 10
2025
Q2 		$5.02M Buy
+192,974
New +$4.65M 2.38% 18

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rosalind Advisors's CGON Position: Q1 2026 in Review

Rosalind Advisors reduced its CG Oncology (CGON) stake by 67% in Q1 2026, selling an estimated $11.3M and leaving 100,000 shares worth $6.77M. The position accounts for 2.72% of the portfolio, ranked #14.

Rosalind Advisors first reported a position in CGON in Q2 2025 and has held it in 4 quarters since. The position peaked at $12.5M in Q4 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Rosalind Advisors held 100,000 shares of CG Oncology worth $6.77M as of Q1 2026.
  • Rosalind Advisors sold 200,000 CG Oncology shares in Q1 2026, an estimated $11.3M.
  • CG Oncology made up 2.72% of Rosalind Advisors's portfolio in Q1 2026, its #14 holding.
  • Rosalind Advisors first reported a position in CG Oncology in Q2 2025 and has held it in 4 quarters since.
  • Rosalind Advisors's CG Oncology position peaked at $12.5M in Q4 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.